Table S3.
Main adverse events related to treatment arms
| Adverse events | RT arm (N=29)
|
RT + erlotinib arm (N=60)
|
||
|---|---|---|---|---|
| AE grade 1–2, n (%) | AE grade 3–5, n (%) | AE grade 1–2, n (%) | AE grade 3–5, n (%) | |
| Cutaneous toxicity | ||||
| Rash/desquamation | 2 (6.9) | 0 (0.0) | 34 (56.7) | 8 (13.3) |
| Radiation skin injury | 14 (48.3) | 1 (3.4) | 23 (38.3) | 2 (3.3) |
| Dry skin | 0 (0.0) | 0 (0.0) | 12 (20.0) | 1 (1.7) |
| Fatigue | 7 (24.1) | 0 (0.0) | 27 (45.0) | 5 (8.3) |
| Hyporexia | 4 (13.8) | 1 (3.4) | 23 (38.3) | 5 (8.3) |
| Gastrointestinal | ||||
| Diarrhea | 2 (6.9) | 1 (3.4) | 26 (43.3) | 4 (6.7) |
| Mucositis | 11 (37.9) | 0 (0.0) | 18 (30.0) | 0 (0.0) |
| Dysphagia | 5 (17.2) | 0 (0.0) | 9 (15.0) | 0 (0.0) |
| Constipation | 0 (0.0) | 0 (0.0) | 11 (18.3) | 0 (0.0) |
| Vomiting | 0 (0.0) | 1 (3.4) | 8 (13.3) | 1 (1.7) |
| Infection | 2 (6.9) | 1 (3.4) | 6 (10.0) | 4 (6.7) |
| Pulmonary | ||||
| Cough | 10 (34.5) | 0 (0.0) | 22 (36.7) | 1 (1.7) |
| Dyspnea | 6 (20.7) | 4 (13.8) | 13 (21.7) | 6 (10.0) |
| Pneumonitis | 3 (10.3) | 3 (10.3) | 9 (15.0) | 2 (3.3) |
| Hematological | ||||
| Anemia | 3 (10.3) | 0 (0.0) | 6 (10.0) | 2 (3.3) |
Note: Main AEs selected occurred in a minimum of ten patients.
Abbreviations: RT, radiotherapy; AE, adverse event.